This Week: US home sales, Tesla earns, Amazon earns

A look at some of the key business events and economic indicators upcoming this week:

HOUSING MARKET BELLWETHER

Economists project that sales of previously occupied homes declined in March from a month earlier.

U.S. home sales surged 11.8% in February, aided by accelerating wages and falling mortgage rates, a combination that's helped improve affordability. The National Association of Realtors is expected to report on Monday that sales slid to a seasonally adjusted annual rate of 5.35 million last month.

Existing home sales, in millions, seasonally adjusted annual rate:

Oct. 5.22

Nov. 5.21

Dec. 5.00

Jan. 4.93

Feb. 5.51

March (est.) 5.35

Source: FactSet

ROUGH ROAD

Tesla's latest quarterly results should provide more details into the company's rocky start to the year.

The electric car maker disclosed earlier this month that it churned out 77,100 vehicles from January to March, well behind the pace it must sustain to fulfill CEO Elon Musk's pledge to manufacture 500,000 cars annually. Tesla serves up its first quarter results Wednesday.

ON A ROLL

Wall Street expects another strong quarterly snapshot from Amazon.

Financial analysts predict the e-commerce giant will report on Thursday that its first quarter earnings and revenue surged past its results from a year earlier. Amazon has boosted its profits in recent quarters by expanding into businesses such as cloud computing services and advertising.

Must Read

Fidel Castro thanks Cuba, criticizes Obama, on 90th birthday

Aug 14, 2016

Fidel Castro thanked Cubans for their well-wishes on his 90th birthday and criticized President Barack Obama in a lengthy letter published in state media

Japan's economy slows to snail's pace as exports falter

Aug 15, 2016

Japan's economy slows in the April-June quarter, as weaker exports and business investment weigh on the faltering recovery of the world's third-largest economy

Patent for J&J's Remicade invalidated, cheaper version looms

Aug 17, 2016

A cheaper version of Johnson & Johnson's top-selling drug, the rheumatoid arthritis treatment Remicade, could be available in the U.S. two years early after a federal judge ruled a key patent on the drug invalid

Search

Obserworld delivers the most accurate and up-to-date world news for the global audience with a thorough research and in-depth interviews. Discover the world through Obserworld.

Contact us: sales[at]obserworld.com